血清糖类抗原125检测在卵巢癌诊断及治疗中的应用研究进展

摘要

Ovarian cancer is a kind of common gynecologic malignant tumor.Also,it is the female tumor disease which has the highest morbidity only after endometrial cancer and cervical cancer , and its mortality ranks first among all gynecologic malignant tumors.The early symptom of ovarian cancer is very secluded.Basi-cally,the majority of patients is diagnosed as late stage when they go to hospital for examination resulting in a poor 5-year survival rate and prognosis.Therefore,the early diagnosis and treatment have become an important means to improve the survival rate and life quality of patients with ovarian cancer .Serum carbohydrate antigen 125(CA125) detection has been widely used in the clinical diagnosis and monitoring of ovarian cancer.%卵巢癌为常见的妇科恶性肿瘤，是继子宫内膜癌、宫颈癌之后发病率最高的女性肿瘤疾病，其病死率居所有妇科恶性肿瘤的第1位。卵巢癌早期症状隐匿，大部分患者入院检查时基本处于晚期，5年生存率较低，预后质量较差，因此早期诊断及治疗已成为提高卵巢癌患者生存率及生存质量的重要手段。目前，血清糖类抗原125（CA125）检测已广泛应用于临床卵巢癌的诊断和监测。